In a study on intraperitoneal metastasis of ovarian cancer, researchers found that deletion of Tissue transglutaminase (TG2), an enzyme overexpressed in primary ovarian cancer, can delay intraperitoneal metastasis of ovarian cancer and reduce ascites. This evidence concerns the gene TGM2 and ovarian carcinoma.